Equillium Announces Initiation of the EQUIP Phase 1b Clinical Trial of Itolizumab for Patients with Uncontrolled Asthma

LA JOLLA, Calif., July 10, 2019 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced it has initiated the EQUIP Phase 1b clinical trial of its CD6 targeted therapy, itolizumab (EQ001), in patients with uncontrolled moderate to severe asthma.

Click to view original post